Recursion Pharmaceuticals Product REC-163964
Recursion Pharmaceuticals Inc (RXRX) announced the initiation of an investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential prophylactic use in high-risk patients.
REC-163964 is a new chemical entity and the first to be . . .
This content is for paid subscribers.
Impacting News May 25, 2021